Clovis Oncology, Inc. CLVSQ

Market cap
$14.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
2.10 2.46 3.93 9.80 55.98 0.00
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(7.57) (7.22) (8.01) (11.30) (47.39) (30.23)
P/B ratio
0.00 0.00 0.00 6.38 8.45 0.00
Price to Tangible BV
0.00 0.00 0.00 29.72 10.99 0.00
EV/Sales
5.30 4.71 6.65 10.38 50.91 0.00
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(4.02) (3.06) (2.94) (2.71) (10.83) (6.25)
EV/FCF
(3.86) (2.97) (2.78) (2.30) (10.66) (6.24)
Quick Ratio
1.36 1.44 2.38 4.24 6.99 4.06
Current Ratio
1.58 1.68 2.75 4.55 7.69 4.26
Net Debt/EBITDA
(2.21) (1.27) (1.06) (0.17) 1.11 (0.06)
Debt/Assets
130.84% 100.73% 102.32% 66.76% 41.41% 77.11%
Debt/Equity
(2.22) (3.84) (3.93) 3.94 0.83 (77.36)
Asset Turnover
0.28 0.26 0.19 0.12 0.10 0.00
Operating CF/Net income
0.74 0.68 0.81 0.99 0.75 0.76
Capex/Depreciation
(0.03) (0.78) (2.06) (7.91) (0.99) (0.01)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00
ROE
120.90% 221.75% 2,881.99% (143.16%) (190.33%) (235.10%)
ROA
(49.06%) (57.91%) (52.23%) (46.04%) (62.99%) (64.78%)
ROIC
(71.85%) (89.52%) (109.91%) (102.86%) (137.10%) (2,059.94%)
Return on Tangible Assets
(333.04%) (267.57%) (161.03%) (77.79%) (63.05%) (159.97%)
Average Days of Receivables
65.93 58.82 52.48 49.32 40.64 566.22
Research and Development Expense of Revenue
125.44% 156.64% 198.00% 242.53% 256.70% 321,960.26%
Selling, General and Administrative Expense of Revenue
86.32% 99.62% 127.81% 184.28% 250.23% 52,219.23%
Intangible Assets out of Total Assets
0.26 0.21 0.19 0.13 0.12 0.21
Share Based Compensation of Revenue
17.11% 30.87% 37.97% 51.46% 80.54% 51,020.51%
Graham Net Nets
(1.77) (1.12) (0.85) (0.15) 0.08 (0.05)
Graham Number
11.20 13.73 23.25 0.00 0.00 4.39
Earnings Yield
(85.24%) (92.71%) (71.24%) (39.37%) (11.34%) (21.12%)
Free Cash Flow Yield
(65.28%) (64.52%) (60.93%) (46.01%) (8.53%) (16.18%)
Revenue per Share
1.29 1.95 2.65 1.83 1.18 0.00
Operating CF per Share
(1.70) (3.00) (6.01) (7.03) (5.55) (6.93)
Capex per Share
0.00 (0.10) (0.35) (1.23) (0.09) (0.02)
Free Cash Flow per Share
(1.70) (3.10) (6.36) (8.26) (5.63) (6.95)
Cash per Share
1.24 2.85 5.51 9.99 11.98 6.92
Shareholders Equity per Share
(2.41) (1.88) (3.23) 2.81 7.81 (0.09)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(2.41) (1.88) (3.23) 2.81 7.81 (0.09)
Free Cash Flow
(196.37) (261.08) (342.38) (430.24) (265.01) (267.38)
Working Capital
72.87 125.90 233.38 446.55 545.42 213.81
Capital Expenditures
(0.31) (8.35) (18.76) (64.24) (4.10) (0.70)
Net Current Asset Value
(553.59) (453.47) (477.39) (144.79) 259.35 (88.78)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.05 0.13 0.67 0.07 8.99
Net Profit Margin
(177.82%) (224.41%) (280.01%) (385.80%) (624.02%) (447,611.54%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.67 0.89 0.60 0.31 1.03 24.12
Cash ROIC
(41.93%) (38.30%) (41.97%) (31.58%) (21.44%) (49.87%)
Accounts Receivable Turnover
5.57 6.99 8.55 10.00 17.62 0.02
Accounts Payable Turnover
1.44 1.40 1.14 1.01 0.90 0.01
Inventory Turnover
1.75 1.44 1.29 0.81 0.31 0.00
Average Days of Payables
256.72 235.87 339.23 471.54 471.05 56,898.29
Days of Inventory on Hand
128.68 271.41 279.06 447.64 855.45 0.00
Average Receivables
26.69 23.54 16.73 9.54 3.15 4.17
Average Payables
27.00 29.46 30.38 21.83 13.03 11.09
Average Inventory
22.20 28.62 26.80 27.29 37.52 —
Average Assets
539.19 637.58 766.58 799.40 549.89 538.97
Average Common Equity
(218.79) (166.50) (13.89) 257.05 182.00 148.51

Fold the line items

Columns are period end dates